Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
GMED's Cash to Debt is ranked higher than
87% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.24 vs. GMED: No Debt )
Ranked among companies with meaningful Cash to Debt only.
GMED' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity to Asset 0.90
GMED's Equity to Asset is ranked higher than
93% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 0.62 vs. GMED: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
GMED' s Equity to Asset Range Over the Past 10 Years
Min: 0.83  Med: 0.86 Max: 0.9
Current: 0.9
0.83
0.9
Interest Coverage No Debt
GMED's Interest Coverage is ranked higher than
87% of the 223 Companies
in the Global Medical Devices industry.

( Industry Median: 69.16 vs. GMED: No Debt )
Ranked among companies with meaningful Interest Coverage only.
GMED' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 6
Z-Score: 17.27
M-Score: -2.57
WACC vs ROIC
4.91%
26.56%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 31.89
GMED's Operating margin (%) is ranked higher than
98% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. GMED: 31.89 )
Ranked among companies with meaningful Operating margin (%) only.
GMED' s Operating margin (%) Range Over the Past 10 Years
Min: 23.4  Med: 29.56 Max: 31.89
Current: 31.89
23.4
31.89
Net-margin (%) 21.19
GMED's Net-margin (%) is ranked higher than
93% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. GMED: 21.19 )
Ranked among companies with meaningful Net-margin (%) only.
GMED' s Net-margin (%) Range Over the Past 10 Years
Min: 15.79  Med: 19.02 Max: 21.19
Current: 21.19
15.79
21.19
ROE (%) 16.56
GMED's ROE (%) is ranked higher than
85% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. GMED: 16.56 )
Ranked among companies with meaningful ROE (%) only.
GMED' s ROE (%) Range Over the Past 10 Years
Min: 15.98  Med: 17.49 Max: 43.04
Current: 16.56
15.98
43.04
ROA (%) 14.35
GMED's ROA (%) is ranked higher than
93% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: -0.39 vs. GMED: 14.35 )
Ranked among companies with meaningful ROA (%) only.
GMED' s ROA (%) Range Over the Past 10 Years
Min: 13.54  Med: 14.67 Max: 36.91
Current: 14.35
13.54
36.91
ROC (Joel Greenblatt) (%) 66.30
GMED's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 312 Companies
in the Global Medical Devices industry.

( Industry Median: 4.23 vs. GMED: 66.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
GMED' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 59.22  Med: 69.97 Max: 139.86
Current: 66.3
59.22
139.86
Revenue Growth (3Y)(%) 10.60
GMED's Revenue Growth (3Y)(%) is ranked higher than
75% of the 232 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. GMED: 10.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
GMED' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 10.6  Med: 10.7 Max: 13.5
Current: 10.6
10.6
13.5
EBITDA Growth (3Y)(%) 12.30
GMED's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. GMED: 12.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
GMED' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 4.5  Med: 9.9 Max: 12.3
Current: 12.3
4.5
12.3
EPS Growth (3Y)(%) 13.50
GMED's EPS Growth (3Y)(%) is ranked higher than
67% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. GMED: 13.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
GMED' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 6.8  Med: 13.1 Max: 13.5
Current: 13.5
6.8
13.5
» GMED's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

GMED Guru Trades in Q3 2015

Jim Simons 143,945 sh (New)
Paul Tudor Jones 54,995 sh (+209.57%)
Steven Cohen Sold Out
Joel Greenblatt 159,743 sh (-13.75%)
» More
Q4 2015

GMED Guru Trades in Q4 2015

John Paulson 132,300 sh (New)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Paul Tudor Jones 29,768 sh (-45.87%)
» More
Q1 2016

GMED Guru Trades in Q1 2016

Jim Simons 346,700 sh (New)
Joel Greenblatt 218,985 sh (New)
John Hussman 200,000 sh (New)
Paul Tudor Jones 100,283 sh (+236.88%)
John Paulson Sold Out
» More
Q2 2016

GMED Guru Trades in Q2 2016

Joel Greenblatt 621,101 sh (+183.63%)
Paul Tudor Jones 117,497 sh (+17.17%)
Steven Cohen 200,000 sh (unchged)
John Hussman Sold Out
Jim Simons 104,700 sh (-69.80%)
» More
» Details

Insider Trades

Latest Guru Trades with GMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:OTCPK:NHNKY, NYSE:PEN, NAS:WMGI, OTCPK:SHWGY, NYSE:NVRO, NAS:ZLTQ, OTCPK:NISOF, NAS:MASI, OTCPK:IOBCF, NAS:LIVN, NAS:BABY, NAS:CYNO, OTCPK:DGWPF, NAS:INGN, NAS:NUVA, OTCPK:GGNDF, OTCPK:EKTAF, NAS:CNMD, NAS:IART, NAS:LDRH » details
Traded in other countries:GM0N.Germany,
Globus Medical Inc is a medical device company focused on developing products that promote healing in patients with musculoskeletal disorders.

Globus Medical Inc was incorporated in Delaware in March 3, 2003. The Company is a medical device company focused exclusively on the design, development and commercialization of musculoskeletal implants. It is currently focused on implants that promote healing in patients with spine disorders. All of its products fall into one of two categories: Innovative Fusion or Disruptive Technologies. The Company's Innovative Fusion products address a spinal fusion surgical procedures. Spinal fusion is a surgical procedure to correct problems with the individual vertebrae, the interlocking bones making up the spine, by preventing movement of the affected bones. It currently offers over 120 products for the treatment of spine disorders. Products in Innovative Fusion includes: CREO, a convenient non-threaded locking cap design that eases building of thoracolumbar fixation constructs to readily adapt to the patient's anatomy and condition, for a range of clinical applications. XPAND, FORTIFY, FORTIFY-I corpectomy devices that incorporate smooth expansion capability, have a range of size options for optimal fit, and are manufactured from titanium or radiolucent polyetheretherketone. COALITION and INDEPENDENCE stand-alone interbody fusion devices, simplify the surgical technique by reducing steps and hardware while providing confident stabilization. Disruptive Technologies represent a shift in the treatment of spine disorders by allowing for novel surgical procedures, improvements to existing surgical procedures, and the treatment of spine disorders by new physician specialties, and surgical intervention earlier in the continuum of care. Products in Disruptive Technologies includes: MIS products which enable a surgeon to perform a procedure less invasively to minimize tissue disruption and maximize native anatomy, for patient recovery and fewer approach-related complications. For example, MARS 3V retractor system facilitates smaller incisions with the use of positionable radiolucent retractor blades to access the surgical site and to allow both direct and radiographic visualization. CALIBER, RISE and recently launched LATIS expandable interbody spacers are designed for reliable, minimally disruptive delivery through small MIS incisions with streamlined implants and instruments. REVOLVE pedicle screw system is designed for MIS screw and rod insertion through small incisions, and utilizes a convenient non-threaded locking cap design. TRANSITION, provide for stabilization that is less rigid than traditional pedicle screw systems for more natural load distribution to help promote fusion while maintaining stability. Other products included are SECURE-C, SECURE-CR, KINEX, MICROFUSE, SHIELD, AFFIRM, among others. Company's competitors include: Medtronic, the DePuy Synthes Companies, Stryker and NuVasive. Alphatec Spine, Orthofix International, Zimmer, LDR, among others. As of December 31, 2013, the Company owned 188 issued U.S. patents and had applicat

Ratios

vs
industry
vs
history
P/E(ttm) 18.86
GMED's P/E(ttm) is ranked higher than
70% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. GMED: 18.86 )
Ranked among companies with meaningful P/E(ttm) only.
GMED' s P/E(ttm) Range Over the Past 10 Years
Min: 12.96  Med: 23.58 Max: 35.64
Current: 18.86
12.96
35.64
Forward P/E 19.23
GMED's Forward P/E is ranked higher than
80% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 24.51 vs. GMED: 19.23 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 18.86
GMED's PE(NRI) is ranked higher than
70% of the 166 Companies
in the Global Medical Devices industry.

( Industry Median: 27.51 vs. GMED: 18.86 )
Ranked among companies with meaningful PE(NRI) only.
GMED' s PE(NRI) Range Over the Past 10 Years
Min: 12.96  Med: 23.58 Max: 35.64
Current: 18.86
12.96
35.64
Price/Owner Earnings (ttm) 22.48
GMED's Price/Owner Earnings (ttm) is ranked higher than
65% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 31.29 vs. GMED: 22.48 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
GMED' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 21.85  Med: 29.88 Max: 74.21
Current: 22.48
21.85
74.21
P/B 2.84
GMED's P/B is ranked higher than
54% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.93 vs. GMED: 2.84 )
Ranked among companies with meaningful P/B only.
GMED' s P/B Range Over the Past 10 Years
Min: 2.45  Med: 3.7 Max: 4.94
Current: 2.84
2.45
4.94
P/S 4.01
GMED's P/S is ranked lower than
58% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 3.21 vs. GMED: 4.01 )
Ranked among companies with meaningful P/S only.
GMED' s P/S Range Over the Past 10 Years
Min: 2.47  Med: 4.24 Max: 5.61
Current: 4.01
2.47
5.61
PFCF 20.97
GMED's PFCF is ranked higher than
66% of the 97 Companies
in the Global Medical Devices industry.

( Industry Median: 27.16 vs. GMED: 20.97 )
Ranked among companies with meaningful PFCF only.
GMED' s PFCF Range Over the Past 10 Years
Min: 18.39  Med: 29.8 Max: 75.46
Current: 20.97
18.39
75.46
POCF 14.65
GMED's POCF is ranked higher than
63% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. GMED: 14.65 )
Ranked among companies with meaningful POCF only.
GMED' s POCF Range Over the Past 10 Years
Min: 12.45  Med: 20.41 Max: 32.2
Current: 14.65
12.45
32.2
EV-to-EBIT 10.67
GMED's EV-to-EBIT is ranked higher than
82% of the 161 Companies
in the Global Medical Devices industry.

( Industry Median: 22.46 vs. GMED: 10.67 )
Ranked among companies with meaningful EV-to-EBIT only.
GMED' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.5  Med: 13.9 Max: 21.3
Current: 10.67
6.5
21.3
EV-to-EBITDA 9.29
GMED's EV-to-EBITDA is ranked higher than
78% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 18.25 vs. GMED: 9.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
GMED' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 12 Max: 17.9
Current: 9.29
5.6
17.9
PEG 1.63
GMED's PEG is ranked higher than
69% of the 74 Companies
in the Global Medical Devices industry.

( Industry Median: 3.22 vs. GMED: 1.63 )
Ranked among companies with meaningful PEG only.
GMED' s PEG Range Over the Past 10 Years
Min: 0  Med: 0 Max: 10104.9
Current: 1.63
0
10104.9
Current Ratio 7.62
GMED's Current Ratio is ranked higher than
89% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. GMED: 7.62 )
Ranked among companies with meaningful Current Ratio only.
GMED' s Current Ratio Range Over the Past 10 Years
Min: 4.88  Med: 6.66 Max: 10.12
Current: 7.62
4.88
10.12
Quick Ratio 6.13
GMED's Quick Ratio is ranked higher than
86% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. GMED: 6.13 )
Ranked among companies with meaningful Quick Ratio only.
GMED' s Quick Ratio Range Over the Past 10 Years
Min: 3.82  Med: 5.6 Max: 8.29
Current: 6.13
3.82
8.29
Days Inventory 287.10
GMED's Days Inventory is ranked lower than
82% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 133.25 vs. GMED: 287.10 )
Ranked among companies with meaningful Days Inventory only.
GMED' s Days Inventory Range Over the Past 10 Years
Min: 125.66  Med: 265.53 Max: 287.1
Current: 287.1
125.66
287.1
Days Sales Outstanding 49.02
GMED's Days Sales Outstanding is ranked higher than
79% of the 267 Companies
in the Global Medical Devices industry.

( Industry Median: 68.90 vs. GMED: 49.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
GMED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.02  Med: 52.05 Max: 58.04
Current: 49.02
49.02
58.04
Days Payable 32.00
GMED's Days Payable is ranked lower than
78% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 58.34 vs. GMED: 32.00 )
Ranked among companies with meaningful Days Payable only.
GMED' s Days Payable Range Over the Past 10 Years
Min: 28.24  Med: 43.9 Max: 52.36
Current: 32
28.24
52.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.50
GMED's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. GMED: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GMED' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.6  Med: -1.5 Max: -0.8
Current: -1.5
-1.6
-0.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.34
GMED's Price/Net Cash is ranked higher than
70% of the 94 Companies
in the Global Medical Devices industry.

( Industry Median: 16.20 vs. GMED: 9.34 )
Ranked among companies with meaningful Price/Net Cash only.
GMED' s Price/Net Cash Range Over the Past 10 Years
Min: 6.32  Med: 13.33 Max: 31.3
Current: 9.34
6.32
31.3
Price/Net Current Asset Value 4.91
GMED's Price/Net Current Asset Value is ranked higher than
65% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 7.35 vs. GMED: 4.91 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
GMED' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.2  Med: 5.83 Max: 7.36
Current: 4.91
3.2
7.36
Price/Tangible Book 3.35
GMED's Price/Tangible Book is ranked higher than
57% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 4.28 vs. GMED: 3.35 )
Ranked among companies with meaningful Price/Tangible Book only.
GMED' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.65  Med: 4.19 Max: 5.51
Current: 3.35
2.65
5.51
Price/Median PS Value 0.93
GMED's Price/Median PS Value is ranked higher than
65% of the 260 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. GMED: 0.93 )
Ranked among companies with meaningful Price/Median PS Value only.
GMED' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.59  Med: 1 Max: 1.33
Current: 0.93
0.59
1.33
Price/Graham Number 1.66
GMED's Price/Graham Number is ranked higher than
60% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. GMED: 1.66 )
Ranked among companies with meaningful Price/Graham Number only.
GMED' s Price/Graham Number Range Over the Past 10 Years
Min: 1.24  Med: 2.12 Max: 2.96
Current: 1.66
1.24
2.96
Earnings Yield (Greenblatt) (%) 9.38
GMED's Earnings Yield (Greenblatt) (%) is ranked higher than
91% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. GMED: 9.38 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
GMED' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.7  Med: 7.2 Max: 15.4
Current: 9.38
4.7
15.4

More Statistics

Revenue (TTM) (Mil) $556.3
EPS (TTM) $ 1.23
Beta0.45
Short Percentage of Float16.87%
52-Week Range $20.48 - 28.60
Shares Outstanding (Mil)95.65

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 575 640 700
EPS ($) 1.19 1.29 1.43
EPS w/o NRI ($) 1.19 1.29 1.43
EPS Growth Rate
(3Y to 5Y Estimate)
9.75%
Dividends Per Share ($)
» More Articles for NYSE:GMED

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Globus Medical Inc, Diplomat Pharmacy Inc, Zendesk Inc, and Amicus Thera Mar 28 2015 

More From Other Websites
ETF’s with exposure to Globus Medical, Inc. : August 12, 2016 Aug 12 2016
Globus Medical, Inc. :GMED-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 Aug 05 2016
GLOBUS MEDICAL INC Financials Aug 03 2016
Globus Medical downgraded by Leerink Partners, Wells Fargo, Canaccord Genuity and Morgan Stanley Jul 27 2016
GLOBUS MEDICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jul 27 2016
Edited Transcript of GMED earnings conference call or presentation 26-Jul-16 9:30pm GMT Jul 27 2016
Globus Medical meets 2Q profit forecasts Jul 26 2016
Globus Medical meets 2Q profit forecasts Jul 26 2016
Alphatec Holdings Announces Sale of International Business to Globus Medical Jul 26 2016
Globus Medical Announces the Acquisition of Alphatec’s International Business Jul 26 2016
Globus Medical Reports Second Quarter 2016 Results Jul 26 2016
GLOBUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition Jul 26 2016
Alphatec Holdings Announces Sale of International Business to Globus Medical Jul 26 2016
Globus Medical Reports Second Quarter 2016 Results Jul 26 2016
Globus Medical Announces the Acquisition of Alphatec’s International Business Jul 26 2016
These 5 Stocks Are Breaking Out This Summer Jul 26 2016
Q2 2016 Globus Medical Inc Earnings Release - After Market Close Jul 26 2016
Med-Instrument Stocks to Post Earnings: EW, CYNO, GMED Jul 25 2016
Globus Medical Schedules Second Quarter 2016 Earnings Release and Conference Call Jul 15 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)